在帕佐帕尼布治疗期间出现症状重度胸梗塞
Cafer Zorkun1, Öykü Alara Eren1
1Department of Cardiology, Istanbul University, Faculty of Medicine, Istanbul, Türkiye.
帕佐帕尼布是一种氨酸激酶抑制剂,可以引起严重的心肌梗塞. 在心脏血管肉瘤患者的剂量减少显著改善了心率,突出显示了监测的必要性.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 心脏病学 心脏病学
背景情况:
- 帕佐帕尼布是一种氨酸激酶抑制剂,向生长因子受体.
- 它用于癌症治疗,但与心血管副作用有关.
- 胸是已知的潜在的不良影响.
更多相关视频
08:56Sterile Pericarditis in Aachener Minipigs As a Model for Atrial Myopathy and Atrial Fibrillation
Published on: September 24, 2021
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
相关概念视频
Decreased pulse rate
There are specific risk factors that can elevate the likelihood of developing bradycardia. Advanced age is a significant factor, with...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Increased pulse rate
Many factors can elevate the risk of developing tachycardia. These include advanced age, a family history of arrhythmias, and an...
